In summary, the combination of zoledronate and IL-2 generates large numbers of Vγ9Vδ2 T cells in vitro with cytotoxic activities against a range of tumour types, even in heavily pretreated patients with advanced malignancy. The gene discussed is IL2; the disease is neoplasm.